Sign Up to like & get
recommendations!
1
Published in 2018 at "Actas dermo-sifiliograficas"
DOI: 10.1016/j.ad.2018.08.002
Abstract: Omalizumab is a monoclonal anti-IgE antibody currently used in the treatment of chronic spontaneous urticaria (CSU) as a third-line option in cases refractory to treatment with the licensed dose of the first-line treatment or up…
read more here.
Keywords:
algorithm guide;
use;
treatment;
rational evidence ... See more keywords